CIEMAT Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2013
NCT02931071
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

CIEMAT/CIBERER/IIS.FJD

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 2)

Fanconi Anemia (Phase 2)

Fanconi Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3